About Index Trending news
Analyze
Pricing
Interface Biologics

Interface Biologics

Interface Biologics

Develops transformative biomedical polymer technology to improve safety of med device. Focused on anti-thrombogenic additives and combo drug delivery devices.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
Venture capital (Series B)
Venture capital
$1,000,000
Employees

Unknown size

Locations
HQ
Headquarters
Venture capital (Series B)
sys-con

Interface Biologics Announces Series B Financing Round With DSM and BDC Capital